共 3 条
Severe cutaneous eruptions following the topical use of preparations containing bufexamac: Is it time to reconsider its registration in Australia?
被引:2
|作者:
Harris, Adam G.
[1
,2
]
Saikal, Samra L.
[1
]
Scurry, Jim
[3
]
Relic, John
[1
]
Nixon, Rosemary L.
[4
]
Chee, Paul
[1
,2
]
机构:
[1] John Hunter Hosp, Dept Dermatol, Newcastle, NSW, Australia
[2] Univ Newcastle, Fac Med, Newcastle, NSW, Australia
[3] John Hunter Hosp, Dept Anat Pathol, Newcastle, NSW, Australia
[4] Skin & Canc Fdn Inc, Occupat Dermatol Res & Educ Ctr, Melbourne, Vic, Australia
关键词:
bufexamac;
contact dermatitis;
drug reaction;
non-steroidal anti-inflammatory agents;
patch tests;
ALLERGIC CONTACT-DERMATITIS;
D O I:
10.1111/ajd.12910
中图分类号:
R75 [皮肤病学与性病学];
学科分类号:
100206 ;
摘要:
Despite being a well-recognised cause of allergic contact dermatitis with an embargo in many countries around the world, bufexamac is available over the counter in topical preparations in Australia. We present a series of patients who developed severe cutaneous eruptions after the topical application of bufexamac containing preparations to highlight the potential risks of this medication, as well as advocate for the reconsideration of its registration by the Therapeutic Goods Administration in Australia.
引用
收藏
页码:53 / 56
页数:4
相关论文